Pharmaceuticals

Sterne Kessler works with branded pharmaceutical companies as well as biosimilars and generic drug companies to protect, enforce, and defend their intellectual property.

Sterne Kessler’s pharmaceuticals practice integrates deep technical knowledge with legal acumen to develop robust patent portfolios, address patent validity challenges at the PTAB, and handle high-profile patent litigation, including Abbreviated New Drug Application (ANDA) and Biologics Price Competition and Innovation Act (BPCIA) matters. We work effectively with our clients to align IP with corporate strategy, and understand the advancements in life sciences that are shaping the IP landscape.Prescription & OTC DrugsOur pharmaceuticals team helps small molecule drug companies across the full range of IP—from patent prosecution and strategy, to opinions and litigation.Infectious Disease TreatmentsSterne Kessler protects and defends drug and vaccine innovations developed to fight against infectious diseases.Generic Drug DevelopmentWe work with generic drug developers to navigate the interface between patent law and the FDA approval process, as well as patent litigation and Abbreviated New Drug Application (ANDA) matters.

Speaking Engagement

November 3, 2026 12:00 AM – 12:00 AM PST

LSPN North America Fall 2026

Articles

October 22, 2026

Will Washington Regulate Biotech Licensing Like Semiconductors? Tracking BINSA and Treasury’s Next Move

Sterne, Kessler, Goldstein & Fox

Articles

October 15, 2026

When the Window Closes: The New Timing of Patent Value in Life Sciences

Managing IP

Articles

October 13, 2026

Patent Claim Quality and Scope: Why What a Patent Claims Matters More Than Whether It Exists

Sterne, Kessler, Goldstein & Fox

Articles

October 7, 2026

Key Takeaways: Navigating Follow-On Patents in Bio-Pharma

Sterne, Kessler, Goldstein & Fox

Firm News

October 6, 2026

Sterne Kessler Advises IntraBio in $2 Billion Sale to Shionogi

Sterne, Kessler, Goldstein & Fox